Senseonics offers the Eversense implantable continuous glucose monitoring system, embedding a small sensor under the skin to provide real‑time glucose readings for up to 365 days (or 180 days) via a rechargeable Bluetooth transmitter and companion mobile app. The platform removes the need for daily sensor changes, minimizes adhesive‑related skin irritation, and delivers clinically calibrated data with HIPAA‑compliant cloud storage for clinician access.
Funding
$35M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HCFounders
Product
Problem
People with diabetes who rely on continuous glucose monitoring face frequent sensor replacements, limited wear time (typically 7‑14 days), adhesive skin irritation, and inaccurate alerts that hinder effective disease management.
Solution
Senseonics offers the Eversense family of implantable continuous glucose monitoring (CGM) systems, including the Eversense 365 and Eversense E3. A tiny sensor is implanted under the skin of the upper arm, providing real‑time glucose data for up to 365 days (Eversense 365) or 180 days (Eversense E3). A removable, rechargeable smart transmitter wirelessly relays glucose readings to a mobile app on iOS, Android, or Apple Watch, delivering calibrated values, trend graphs, and predictive alerts. The system eliminates the need for daily sensor changes, reduces adhesive‑related skin issues, and delivers high‑accuracy measurements with minimal false alarms. Integration with insurance programs and Medicare helps lower out‑of‑pocket costs, while clinicians can access data through secure cloud services for therapeutic decisions.
Target Audience
The primary customers are adults with Type 1 or Type 2 diabetes who use insulin therapy and require reliable, long‑term glucose monitoring, as well as endocrinologists, diabetes clinics, and other healthcare providers prescribing CGM solutions.
Features
- Implantable glucose sensor with silicone housing, approved for up to 365 days (Eversense 365) or 180 days (Eversense E3) of continuous operation.
- Removable, rechargeable smart transmitter using Bluetooth Low Energy (BLE) to send encrypted glucose data to a companion mobile app.
- Mobile application (iOS, Android, Apple Watch) provides real‑time glucose values, trend visualizations, and predictive low‑glucose alerts.
- Calibration required once per week (Eversense 365) or once per day (Eversense E3) after initial warm‑up period, ensuring clinical‑grade accuracy.
- Gentle, silicone‑based adhesive that is changed daily, minimizing skin irritation and allowing transmitter removal without sensor waste.
- Cloud‑hosted data platform with HIPAA‑compliant storage, enabling clinicians to review longitudinal glucose profiles and generate reports.
- Compatibility with major commercial health plans and Medicare, supported by a patient assistance program to reduce cost barriers.
- FDA‑cleared device with extensive patent portfolio covering sensor, transmitter, and software technologies.